KTTANasdaqPharmaceutical PreparationsUS GAAP · USD

Pasithea Therapeutics Corp.

Pasithea Therapeutics Corp. is a U.S.-based biotechnology company focused on discovering and developing therapies for central nervous system and other serious diseases. Its portfolio includes clinical-stage and discovery-stage programs, with operations conducted through a group of U.S., Australian, Portuguese, and former U.K. subsidiaries.

Kysy yhtiöstä
Liikevoitto (EBIT)−20,9milj. USD
−46,4 %v/v
Nettotulos−20,4milj. USD
−46,9 %v/v

Tilikausi 2025 · muutos edellisvuodesta

Kehitys 2021–2025

−25−20−15−10−505milj. USD2021: 0,02 milj. USD2021: EBIT −4,5 milj. USD20212022: 0,49 milj. USD2022: EBIT −15 milj. USD20222023: EBIT −16 milj. USD20232024: EBIT −14 milj. USD20242025: EBIT −21 milj. USD2025−21
LiikevaihtoLiikevoitto (EBIT)

Liiketoiminta

Osuus liikevaihdosta
Clinical-stage drug programs0 %

Therapeutic candidates being advanced through clinical development and regulatory review.

Discovery-stage programs0 %

Early-stage research programs aimed at identifying new drug candidates for CNS diseases.

Preclinical research and development0 %

Laboratory and translational work supporting target validation and candidate selection.

Corporate and development operations100 %

Internal functions supporting financing, IP, and advancement of the pipeline.

Asiakkaat

Pasithea does not appear to sell commercial products yet; its primary stakeholders are regulators, clinical investigators, and future healthcare customers that would use approved therapies. The eventual end customers would be patients and physicians in neurology and psychiatry, while near-term counterparties include research partners, capital providers, and clinical service providers supporting development.

ALS patients and treating clinicians

Future users of PAS-003 if development succeeds; the program targets unmet need in amyotrophic lateral sclerosis.

Schizophrenia patients and psychiatrists

Future users of PAS-001 if it advances successfully; the program is aimed at a major CNS indication.

Clinical research ecosystem

Trial sites, investigators, CROs, and regulators that support preclinical and clinical advancement.

Capital providers and strategic partners

Equity, debt, and collaboration counterparties that fund development and extend operating runway.

Strategia

Pasithea’s strategy is to advance its pipeline through discovery, preclinical work, and clinical development while preserving access to external capital. The company also emphasizes maintaining intellectual property, building development capabilities, and preparing for eventual commercialization if any candidate is approved.

Advance lead and discovery programsLyhyt aikaväli

Pipeline progression is the main value driver for a pre-commercial biotech.

Raise external capitalLyhyt aikaväli

Development programs require funding before any product revenue exists.

Protect and expand intellectual propertyKeskipitkä aikaväli

IP underpins exclusivity and future partnering or commercialization value.

Maantiede

Pasithea is headquartered in the United States and operates through subsidiaries in the U.S. and Australia, with former entities in the U.K. and Portugal now discontinued. Its business is geographically shaped by where research, clinical development, and corporate financing activities can be conducted rather than by commercial sales markets.

Riskit

Pasithea faces the typical risks of a pre-revenue biotech: clinical failure, regulatory delay, and the possibility that additional financing is unavailable or dilutive. It also has company-specific listing and capital-market risks, including Nasdaq bid-price compliance and restrictions tied to its public float.

Järjestetty vakavuuden mukaan
MatalaKohtalainenKorkeaMatalaKohtalainenKorkeaVaikutus →Todennäköisyys →Financing shortfall1Nasdaq listing compliance3
Vaikutus on riskin vakavuus ja todennäköisyys sen toteutumisen todennäköisyys lähivuosina, molemmat arvioitu yhtiön raporttien perusteella. Numerot vastaavat listaa.
  1. Financing shortfallVaikutus: KriittinenTodennäköisyys: Matala

    The company expects to need additional capital before it can fund development and operations.

    KohdistuuEquityDebtATMShelf offerings
  2. Pipeline development failureVaikutus: Kriittinen

    Drug candidates may not show sufficient safety or efficacy in preclinical or clinical testing.

    KohdistuuPAS-004PAS-003PAS-001
  3. Nasdaq listing complianceVaikutus: KorkeaTodennäköisyys: Korkea

    Failure to maintain bid-price and other listing requirements could trigger delisting.

    Kohdistuu: Common stock and public warrants

  4. Competitive therapeutic landscapeVaikutus: Keskitaso

    Other approved or emerging therapies could limit market opportunity for its candidates.

    Kohdistuu: ALS and schizophrenia programs

Kirjanpito

Harkinnanvaraiset erät
Research and development expense

Clinical and preclinical program costs are expensed as incurred and drive operating results.

Vaikutus: Affects operating loss and cash burn

Stock-based compensation

Equity awards are a common compensation tool in development-stage biotech companies.

Vaikutus: Can materially increase reported expenses

Fair value measurements

Valuation of warrants or other instruments can create non-cash gains or losses.

Vaikutus: Affects net income volatility

Going-concern assessment

Liquidity depends on future financing and development milestones.

Vaikutus: Important for solvency and disclosure analysis

Samankaltaisia listattuja yhtiöitä

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

Lisata Therapeutics, Inc

LSTA · Pharmaceutical Preparations

Prothena Corporation plc

PRTA · Pharmaceutical Preparations

MapLight Therapeutics, Inc.

MPLT · Pharmaceutical Preparations

Passage BIO, Inc.

PASG · Biological Products, (No Diagnostic Substances)

NuCana plc

NCNA · Pharmaceutical Preparations

Grace Therapeutics, Inc.

GRCE · Pharmaceutical Preparations

Päivitetty: 24.9.2026

Pasithea Therapeutics Corp. (Nasdaq) – Pharmaceutical Preparations | Analyysi – Clarifo